Introducing TRYNGOLZA

The first and only FDA-approved therapy for adults with familial chylomicronemia syndrome (FCS)1

Microscope Icon

Trial and results

See the results of the pivotal Balance trial

Group Icon

Safety

TRYNGOLZA demonstrated a well-
tolerated safety profile1

Dosing Icon

Dosing and administration

TRYNGOLZA is administered via a 
convenient autoinjector1,2

Shaking Hands Icon

Support

The Ionis Every StepTM program is here for 
you and your patients, every step of the way

For your adult patients with familial chylomicronemia syndrome (FCS), it’s time to

significant reductions in triglycerides1*

TRYNGOLZA is proven to significantly reduce triglyceride levels 
in adults with FCS when used as an adjunct to diet.1

*In the Balance clinical trial, TRYNGOLZA demonstrated a significant mean change of -42.5% in fasting triglycerides from baseline to Month 6 compared with placebo (P=0.0084).1

Not a real patient; actor portrayal.

TRYNGOLZA is a once-monthly subcutaneous injection, self-administered via autoinjector.1

TRYNGOLZA Autoinjector